Huntington's disease is a genetic neurodegenerative disorder that affects both motor and cognitive function and gradually reduces the independence and quality of life of those affected. One of the ...

SAN DIEGO, Sept. 30, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced interim results from the ongoing open-label KINECT®-HD2 study of INGREZZA® (valbenazine) capsules ...

Neurocrine Biosciences is a pharmaceutical company specializing in the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company recently submitted a proposal for the use ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The FDA approved Ingrezza due to results from KINECT-HD, ...

Motor symptoms of Huntington's disease (HD) are so central to the genetic neurodegenerative disease that it was long called Huntington's chorea. However, they're often untreated, despite a growing ...

The phase 3 KINECT-HD study included 128 adults 18 to 75 years of age who were diagnosed with chorea associated with HD. Positive topline data were announced from a phase 3 study evaluating the ...

The drug valbenazine statistically improves chorea, a movement disorder commonly associated with Huntington's disease, when compared to a placebo. The drug valbenazine statistically improves chorea, a ...

Chorea Huntington (known as "Veitstanz" in German) is a rare brain disorder that causes uncontrollable, jerky movements in individuals. Photo: Getty Images/Science Photo Library RF Huntington’s ...

Neurocrine Biosciences announced data from a phase 3 trial of Ingrezza that showed it reduced chorea severity among patients with Huntington’s disease. The trial, called KINECT-HD, examined the ...

SAN DIEGO, Nov. 2, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced interim results from the ongoing open-label KINECT®-HD2 study about INGREZZA® (valbenazine) capsules ...

SAN DIEGO, Aug. 28, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data on now FDA-approved INGREZZA® (valbenazine) capsules for the treatment of adults with ...